{"id":12439,"date":"2008-07-17T15:30:00","date_gmt":"2008-07-17T13:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/rassegna-stampa-farmaceutica-dal-15-al-17-luglio-di-aboutpharma\/"},"modified":"2008-07-17T15:30:00","modified_gmt":"2008-07-17T13:30:00","slug":"rassegna-stampa-farmaceutica-dal-15-al-17-luglio-di-aboutpharma","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/rassegna-stampa-farmaceutica-dal-15-al-17-luglio-di-aboutpharma\/","title":{"rendered":"PHARMACEUTICAL PRESS REVIEW from July 15th to 17th of AboutPharma"},"content":{"rendered":"<p class=\"MsoNormal\"><strong><strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\">Press Review from<\/span><\/font><\/strong><\/strong><font face=\"Arial\" color=\"#ff0000\" size=\"4\"><span style=\"font-size: 14pt; color: red; font-family: Arial\"> <strong><span style=\"font-weight: bold\">15<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/07\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong>&nbsp;<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">to the<\/span><\/font><\/strong><\/strong>&nbsp;<strong><span style=\"font-weight: bold\">17<strong><strong><font face=\"Arial\"><span style=\"font-family: Arial\">\/07\/08<\/span><\/font><\/strong><\/strong><\/span><\/strong><\/span><\/font>&nbsp;<\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Quarterly increase for Novartis: +12%<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span lang=\"EN-GB\" style=\"font-size: 10pt; font-family: Arial\">(The Wall Street Journal online, Les Echos online - July 17, 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">In the 2nd quarter of 2008, Novartis reported net income of $2.25 billion, compared with 2.01 in 2007 and sales increased by 14% to $10.7 billion, driven primarily by the prescription division -drugs&#039;, which scored a +14%.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17309\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17309<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">&quot;<personname w_st=\"on\" productid=\"La Santa Rita\">The Santa Rita<\/personname> cancel horror surgery&quot;<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(<personname w_st=\"on\" productid=\"la Repubblica Milano\">the Milan Republic<\/personname>: p. VII \u2013 17 July 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">In the reopening plan of the Santa Rita presented to the ASL by the new management of the clinic, there is no trace of the thoracic surgery department, where Pier Paolo Brega Massone, the doctor accused of murdering 5 patients, operated for years. The ASL is X-raying the industrial plan of Santa Rita: &#039;It goes in the requested direction&#039; says the General Manager Cristina Cant\u00f9. Meanwhile, the union is pressing for the clinic to reopen as soon as possible.<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><a href=\"http:\/\/www.aboutpharma.it\/notizia.asp?id=17315\" target=\"_blank\" rel=\"noopener\">http:\/\/www.aboutpharma.it\/notizia.asp?id=17315<\/a><\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\"><\/p>\n<p>&nbsp;<\/p>\n<p><\/span><\/font><\/p>\n<p class=\"MsoNormal\"><strong><font face=\"Arial\" color=\"#0000ff\" size=\"2\"><span style=\"font-weight: bold; font-size: 10pt; color: blue; font-family: Arial\">Milan: boom in psychiatric drugs<\/p>\n<p><\/span><\/font><\/strong><\/p>\n<p class=\"MsoNormal\"><font face=\"Arial\" size=\"2\"><span style=\"font-size: 10pt; font-family: Arial\">(Corriere della Sera Milan: page 3, Libero Milan: page 51 \u2013 17 July 2008)<\/p>\n<p><\/span><\/font><\/p>\n<p","protected":false},"excerpt":{"rendered":"<p>Rassegna Stampa dal 15\/07\/08&nbsp;al&nbsp;17\/07\/08&nbsp; Trimestrale in rialzo per Novartis: +12% (The Wall Street Journal online, Les Echos online &#8211; 17 luglio 2008) Nel 2&deg; trimestre del 2008, Novartis ha registrato un risultato netto di 2,25 mld di dollari, rispetto ai 2,01 del 2007 e le vendite sono cresciute del 14% a 10,7 mld di dollari, &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-12439","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=12439"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/12439\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=12439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=12439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=12439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}